Coverage / CTXR / Trade Card

CTXR

Citius Pharmaceuticals Inc

OPPORTUNISTIC BUY 2026-08-09 Data 34 days old USD 0.68 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
54

Position levels

Currenttoday
USD 0.68
Buy <=wait / entry
USD 0.43
Trim >=take some off
USD 0.80
Thesis breakThe thesis would be invalidated by a failure to sustain LYMPHIR revenue growth, ...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case20%100 / 10020.0
Base case50%62 / 10031.0
Bear case30%10 / 1003.0
Weighted conviction54 / 100 - OPPORTUNISTIC BUY

Top risks

  • LYMPHIR approval with commercial distribution beginning December 2025
  • Q2 2026 EPS of -$1.00 versus estimate of -$0.32 (miss)
  • Strong Buy analyst ratings with 12-month price target of $4 per share
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.